Vivoxid Ltd enters collaboration with Osspol Ab
Turku Science Park based biomaterial company Vivoxid Ltd
and Swedish Osspol Ab have signed an Option Agreement
to jointly develop and commercially exploit Vivoxid’s
MetALive™ surface modification technology in Osspol’s
new design dental implant.
The patented MetAlive™ technology has been developed in Turku Biomaterials Research Group. As a result
of the surface modification, the implant bonds to soft tissue thus improving greatly its clinical performance.
Osspol will pay a signing fee to Vivoxid and later on, depending on the results of the development work,
Vivoxid will also receive milestone payments and revenues based on sales of dental implants treated with
MetAlive™. As a result of the agreement, the parties will jointly carry out clinical and technical development
funded by Vivoxid.
- We are very enthusiastic with this agreement. Osspol has an extremely competitive dental implant system
under development. Together with Osspol Vivoxid has an opportunity to enter into a major dental market
(world wide market over 1 billion USD) with MetAlive™. We will improve the quality of the patient treatment
and increase revenues for both companies. This is an excellent opening of the commercial exploitation of
this technology and speeds up its other commercial opportunities, says Kauko Kurkela, managing director of
Vivoxid.
- The interface between bone and implant is well documented and clinically very successful. Vivoxid’s new
MetAlive™ technology shows very promising indications that we are now also able to achieve integration
between gingiva and the implant component as well. This will undoubtedly bring dental implant treatment to
a new level of clinical success. Adding the MetAlive™ technology to Osspol will further strengthen the clinical
benefits and bring the company yet another sustainable competitive feature, says Dr. Hans Berglund, of
Osspol Ab.
Osspol Ab
Osspol is a subsidiary of Biolin Ab, a medtech and biotech development company listed on the Stockholm
Stock Exchange. Osspol is currently developing an innovative and patented dental implant system focusing
on an optimal clinical result as well as an attractive business model for the potential customers within implant
dentistry.
Vivoxid Ltd.
Vivoxid Ltd, Turku, Finland develops, manufactures and markets new biomaterial products for tissue repair
and regeneration in dentistry, head and neck, orthopaedic and wound care areas. In addition to bioactive
glass products it develops bioactive glass / polymer composites, cellulose sponge products and titanium
oxide surface modification.
Vivoxid launched in Europe last year AbMinCranio™ bioactive glass products for the treatment of sinus
obliteration, repair of frontal bone and repair of orbital floor.
For further information contact
CEO Kauko Kurkela, Vivoxid Ltd, tel. +358 2 2518466
Email: kauko.kurkela@vivoxid.com
CEO Hans Berglund, Osspol AB tel. +46 70 2244404
Email: hans.g.berglund@telia.com